Published in Eur Urol on August 23, 2006
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett (2006) 1.13
GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol (2014) 1.12
Cancer stem cells and hepatocellular carcinoma. Cancer Biol Ther (2009) 1.11
DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn (2009) 1.08
Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05
CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol (2008) 1.00
Promoter hypermethylation in prostate cancer. Cancer Control (2010) 0.99
APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet (2013) 0.92
Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation. Neuro Oncol (2011) 0.91
Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation. BMC Cancer (2009) 0.89
DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol (2012) 0.88
WWOX expression in colorectal cancer--a real-time quantitative RT-PCR study. Tumour Biol (2011) 0.87
Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer. Chin J Cancer Res (2011) 0.84
Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis. PLoS One (2013) 0.82
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. PLoS One (2013) 0.81
GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. World J Urol (2011) 0.80
Epigenetic regulation of prostate cancer. Clin Epigenetics (2011) 0.79
Epigenetic regulations of inflammatory cyclooxygenase-derived prostanoids: molecular basis and pathophysiological consequences. Mediators Inflamm (2015) 0.75
Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors. PLoS One (2015) 0.75
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Retracted Cytohesins are cytoplasmic ErbB receptor activators. Cell (2010) 2.74
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn (2007) 2.35
Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU Int (2013) 2.10
Comparison of blood group versus HLA-dependent transplantation and its influence on donor kidney survival. Nephrol Dial Transplant (2002) 2.06
Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature (2010) 2.01
Primitive neuroectodermal tumor: rare, highly aggressive differential diagnosis in urologic malignancies. Urology (2006) 1.94
Treatment of penile strangulation caused by constricting devices. Urology (2002) 1.81
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res (2012) 1.65
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol (2012) 1.50
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest (2013) 1.41
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol (2007) 1.26
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.21
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst (2009) 1.21
Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol (2012) 1.20
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov (2013) 1.18
CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate (2008) 1.16
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
Global levels of histone modifications predict prostate cancer recurrence. Prostate (2010) 1.11
The effect of sealing with a fixed combination of collagen matrix-bound coagulation factors on the healing of colonic anastomoses in experimental high-risk mice models. Langenbecks Arch Surg (2010) 1.10
Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer (2010) 1.09
Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat (2011) 1.07
Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol (2012) 1.07
Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn (2015) 1.04
Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer (2008) 1.00
MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett (2008) 1.00
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol (2011) 1.00
Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol (2013) 0.98
Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol (2012) 0.98
Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int (2011) 0.97
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res (2009) 0.97
Small intestine submucosa in urethral stricture repair in a consecutive series. Urology (2006) 0.97
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. Histochem Cell Biol (2006) 0.97
Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci (2010) 0.97
Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer (2011) 0.95
Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol (2008) 0.95
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int (2009) 0.94
Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int (2011) 0.94
Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology (2008) 0.94
Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol (2007) 0.94
Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: are results predictable? Clin Genitourin Cancer (2011) 0.94
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov (2014) 0.93
Control of glycolytic oscillations by temperature. Biophys J (2004) 0.93
CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol (2009) 0.93
Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood (2012) 0.93
Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol (2010) 0.93
Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci (2014) 0.93
Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU Int (2008) 0.93
Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Hum Pathol (2008) 0.93
The role of molecular diagnostics in cancer diagnosis and treatment. Onkologie (2012) 0.93
Impairment of long-term graft function after kidney transplantation by intraoperative vascular complications. Int Urol Nephrol (2008) 0.92